Symbols

VIR

Vir Biotechnology·NASDAQ

--(--)

VIR fundamentals

VIR Q4 2025 Earnings

Vir Biotechnology (VIR) released its earnings on Feb 23, 2026: revenue was 64.07M (YoY +417.78%), beat estimates; EPS was -0.31 (YoY +59.21%), beat estimates.

Revenue / YoY

64.07M

+417.78%

EPS / YoY

-0.31

+59.21%

Report date

Feb 23, 2026

VIR Earnings Call Summary for Q4,2025

$1.7B Collaboration with Astellas: VIR-5500 gains global reach with 50-50 U.S. profits and ex-U.S. royalties, reducing Vir's near-term spend.
Phase I Success: 82% PSA50, 50% PSA90, no Grade 3+ CRS, positioning as best-in-class T-cell engager.
PRO-XTEN Platform Validation: Dual masking technology enables higher doses with reduced toxicity, supporting 7 preclinical programs.
Financial Strength: $782M cash post-collaboration, 2025 expenses down 10-23%, runway to Q2 2028.

Earnings

EPS

Revenue

Revenue & Expenses

VIR has released its 2025 Q4 earnings report, with revenue of 64.07M, reflecting a YoY change of 417.78%, and net profit of -42.92M, showing a YoY change of 58.96%. The Sankey diagram below clearly presents VIR's revenue sources and cost distribution.

Key Indicators

Vir Biotechnology (VIR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Vir Biotechnology (VIR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Vir Biotechnology (VIR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Vir Biotechnology (VIR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown